Key Takeaways ADAG shares rose 13.8% post Fast Track tag for muzastotug plus pembrolizumab in MSS mCRC.Adagene says its SAFEbody-based CTLA-4 antibody aims to improve survival versus conventional therapies.ADAG plans a randomized phase II study with ORR as the primary endpoint and targets a phase III start in 2027.Adagene Inc. (ADAG) announced that the FDA has granted Fast Track designation to its lead clinical-stage immuno-oncology candidate, muzastotug (ADG126).The designation was granted to muzastotug in ...